Drug Profile
Sodium phenylbutyrate - Digna Biotech
Alternative Names: 4-PBALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Digna Biotech; University of Navarra
- Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 20 Jul 2015 Discontinued - Phase-II for Alzheimer's disease in Europe (unspecified route)
- 27 May 2010 Phase-II clinical trials in Alzheimer's disease in Europe (unspecified route)